<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas M File, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Julio A Ramirez, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheila Bond, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community, as distinguished from hospital-acquired (nosocomial) pneumonia (HAP).
        </p>
        <p>
         CAP is a common and potentially serious illness [
         <a href="#rid1">
          1,2
         </a>
         ]. It is associated with considerable morbidity and mortality, particularly in older adult patients and those with significant comorbidities. (See
         <a class="medical medical_review" href="/z/d/html/7016.html" rel="external">
          "Morbidity and mortality associated with community-acquired pneumonia in adults"
         </a>
         .)
        </p>
        <p>
         The epidemiology, pathogenesis, and microbiology of CAP in adults will be reviewed here. A variety of other important issues related to CAP are discussed separately. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">
          "Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7018.html" rel="external">
          "Sputum cultures for the evaluation of bacterial pneumonia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7022.html" rel="external">
          "Community-acquired pneumonia in adults: Assessing severity and determining the appropriate site of care"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">
          "Treatment of community-acquired pneumonia in adults in the outpatient setting"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7024.html" rel="external">
          "Aspiration pneumonia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1402.html" rel="external">
          "Epidemiology of pulmonary infections in immunocompromised patients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6992.html" rel="external">
          "Nonresolving pneumonia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7016.html" rel="external">
          "Morbidity and mortality associated with community-acquired pneumonia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">
          "COVID-19: Epidemiology, virology, and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H3412718455">
         <span class="h2">
          Community-acquired pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall incidence of CAP in adults is estimated at approximately 16 to 23 cases per 1000 persons per year; the rate rises with age [
         <a href="#rid3">
          3-5
         </a>
         ]. In the United States, approximately 30 percent of patients with CAP are hospitalized, with an incidence of approximately 5 to 7 CAP hospitalizations per 1000 persons per year [
         <a href="#rid3">
          3-5
         </a>
         ]. There is seasonal variation, with more cases occurring during the winter months. The rates of pneumonia are higher for men than for women and for Black persons compared with White persons. The etiology of CAP varies by geographic region; however,
         <em>
          Streptococcus pneumoniae
         </em>
         is the most commonly identified bacterial cause of CAP worldwide. Viruses are common causes of CAP as well [
         <a href="#rid6">
          6,7
         </a>
         ]. The microbiology of CAP is discussed in greater detail below. (See
         <a class="local">
          'Microbiology'
         </a>
         below.)
        </p>
        <p>
         In 2005, pneumonia and influenza combined was the eighth most common cause of death in the United States and the seventh most common cause of death in Canada [
         <a href="#rid8">
          8,9
         </a>
         ]. There were over 60,000 deaths due to pneumonia in the United States. Mortality is highest for CAP patients who require hospitalization. Data from the Centers for Medicare and Medicaid Services database estimate the 30-day mortality rate of CAP patients (mostly those &gt;65 years of age) requiring admission to the hospital in the United States to be approximately 12 percent [
         <a href="#rid10">
          10
         </a>
         ]. Overall mortality may also vary according to geographic location (United States/Canada 7.3 percent; Europe 9.1 percent; Latin America 13.3 percent); however, following adjustment for confounding variables, these differences are often reduced [
         <a href="#rid11">
          11
         </a>
         ]. All-cause mortality in patients with CAP is as high as 28 percent within one year. Given the aging population in North America, it is expected that the burden of CAP will increase. (See
         <a class="medical medical_review" href="/z/d/html/7016.html" rel="external">
          "Morbidity and mortality associated with community-acquired pneumonia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2275274984">
         <span class="h2">
          Health care-associated pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community, as distinguished from hospital-acquired (nosocomial) pneumonia (HAP).
        </p>
        <p>
         A third category of pneumonia, designated health care-associated pneumonia (HCAP), was included in prior HAP guidelines [
         <a href="#rid12">
          12
         </a>
         ] (but not current HAP guidelines [
         <a href="#rid13">
          13
         </a>
         ]) to identify patients thought to be at increased risk for multidrug-resistant (MDR) pathogens coming from community settings. HCAP referred to pneumonia acquired in health care facilities such as nursing homes, hemodialysis centers, and outpatient clinics or a hospitalization within the past three months. The rationale for the separate designation of HCAP (and its association with HAP) was that patients with HCAP were thought to be at higher risk for MDR organisms. However, several studies have shown that many patients defined as having HCAP are not at high risk for MDR pathogens [
         <a href="#rid14">
          14-16
         </a>
         ], and that this designation is not a good predictor of who will have an infection with an MDR organism [
         <a href="#rid17">
          17
         </a>
         ]. Furthermore, although interaction with the health care system is potentially a risk for MDR pathogens, underlying patient characteristics are also important independent determinants of risk for MDR pathogens and mortality. It is anticipated that patients previously designated as HCAP will be included in the next update of the Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) CAP guidelines because patients with HCAP frequently present from the community and are initially cared for in emergency departments.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The lungs are constantly exposed to particulate material and microbes that are present in the upper airways and, by microaspiration, enter the lower respiratory tract. Contrary to longstanding belief, the lower respiratory tract is not sterile. Using culture-independent techniques, investigators have shown that healthy lower airways contain some bacterial species that are also found in the upper respiratory tract, such as
         <em>
          Prevotella
         </em>
         spp,
         <em>
          Veillonella
         </em>
         spp, and
         <em>
          Streptococcus
         </em>
         spp [
         <a href="#rid18">
          18
         </a>
         ]. However, pulmonary host defenses are important for maintaining the microbiome at low levels and devoid of conventional pathogens. These host defenses can be categorized as innate (nonspecific) or acquired (specific). The development of community-acquired pneumonia (CAP) indicates either a defect in host defenses, exposure to a particularly virulent microorganism, or an overwhelming inoculum [
         <a href="#rid19">
          19-21
         </a>
         ].
        </p>
        <p>
         Microaspiration is the most common mechanism through which the constituents of the microbiota and pathogens reach the lung. Hematogenous spread from a distant infected site, direct spread from a contiguous focus, and macroaspiration are other mechanisms whereby pathogens gain access to the lung.
        </p>
        <p class="headingAnchor" id="H594520523">
         <span class="h2">
          Local pathogen multiplication
         </span>
         <span class="headingEndMark">
          —
         </span>
         New understanding of the human microbiome indicates that the lower airways and alveolar space in the healthy lung are not free of microorganisms, as previously considered [
         <a href="#rid18">
          18
         </a>
         ]. Bacteria and viruses are part of the normal lung microbiome. The bacteria that constitute the normal alveolar flora are predominantly anaerobic organisms and microaerophilic streptococci. The pathogenesis of some cases of CAP may involve the uncontrolled multiplication of some of these bacteria already present in the alveoli.
        </p>
        <p>
         Since the common bacterial pathogens associated with CAP are not part of the normal alveolar microbiome, they must arrive and multiply in the alveoli. Local multiplication may be prevented by the killing of organisms by the alveolar macrophage. The presence of a normal alveolar flora may also interfere with the local multiplication of newly arrived pathogenic organisms. The uncontrolled alveolar multiplication of organisms is likely due to a combination of arrival to the alveolar space of a particularly virulent microorganism and abnormal host defenses. In a host prone to aspiration, local multiplication of less virulent bacteria, usually anaerobes from the upper airway, may occur due to an overwhelming inoculum (see
         <a class="medical medical_review" href="/z/d/html/7024.html" rel="external">
          "Aspiration pneumonia in adults"
         </a>
         ). Tobacco use and alcohol consumption are common host conditions that favor development of CAP by altering the normal host defense mechanisms.
        </p>
        <p class="headingAnchor" id="H3393752232">
         <span class="h2">
          Local inflammatory response
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the local alveolar macrophage fails to contain the local multiplication of the pathogenic organism, the macrophage will produce a series of cytokines to bring new phagocytes to the alveolar space. Local production of cytokines will generate an inflammatory response with increased local microvascular permeability. This will facilitate the movement of white blood cells (WBCs), proteins, and fluid into the alveolar space. The arrival of neutrophils, lymphocytes, and antibodies will aid the macrophages in the killing of alveolar pathogens.
        </p>
        <p class="headingAnchor" id="H3425127123">
         <span class="h2">
          Systemic inflammatory response
         </span>
         <span class="headingEndMark">
          —
         </span>
         The production of cytokines and chemokines by activated cells in the alveolar space will spill into the systemic circulation and produce a systemic inflammatory response. The systemic response will aid the local response primarily by activating production of WBCs by the bone marrow, increasing cardiac output, and elevating body temperature. The combination of the local and systemic inflammatory responses can be seen as a normal or physiologic host response to prevent the spread of infection and to control the local alveolar infection. The host local and systemic inflammatory responses explain the majority of the patient's clinical features.
        </p>
        <p class="headingAnchor" id="H1231815722">
         <span class="h2">
          Dysregulated inflammatory response
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some patients, the initial systemic inflammatory response can become dysregulated. This abnormal response will be associated with tissue injury and organ dysfunction. The progression from a physiologic to a dysregulated systemic inflammatory response indicates that pneumonia is now complicated with sepsis [
         <a href="#rid22">
          22
         </a>
         ]. Patients with CAP and sepsis are at risk of progression to organ failure.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Virulence factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some microorganisms have developed specific mechanisms to overcome pulmonary host defenses and establish infection [
         <a href="#rid19">
          19-21
         </a>
         ]. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Chlamydia pneumoniae
         </em>
         produces a ciliostatic factor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Mycoplasma pneumoniae
         </em>
         can shear off cilia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Influenza virus markedly reduces tracheal mucus velocity within hours of onset of infection and for up to 12 weeks postinfection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          S. pneumoniae
         </em>
         and
         <em>
          Neisseria meningitidis
         </em>
         produce proteases that can split secretory immunoglobulin (Ig)A. In addition, the pneumococcus produces other virulence factors, including the capsule that inhibits phagocytosis, pneumolysin, a thiol-activated cytolysin that interacts with cholesterol in host cell membranes, neuraminidase, and hyaluronidase.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Mycobacterium
         </em>
         spp,
         <em>
          Nocardia
         </em>
         spp, and
         <em>
          Legionella
         </em>
         spp are resistant to the microbicidal activity of phagocytes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Predisposing host conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to microbial virulence factors, diseases and conditions in the host may lead to impairment of pulmonary defense and increased risk of CAP  (
         <a class="graphic graphic_table graphicRef52808" href="/z/d/graphic/52808.html" rel="external">
          table 1
         </a>
         ). These include [
         <a href="#rid23">
          23
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older age (marked increase in pneumonia incidence among adults &gt;65 years old)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic lung diseases and/or other disorders that impair airway clearance:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic obstructive pulmonary disease (COPD)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cystic fibrosis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bronchiectasis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Heart failure
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bronchial obstruction due to stenosis, tumor, or foreign body
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lung cancer
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Previous episode of pneumonia (presumably due to scarring)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immotile cilia syndrome and Kartagener syndrome (ciliary dysfunction, situs inversus, sinusitis, bronchiectasis)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conditions that increase risk of macroaspiration of stomach contents and/or microaspiration of upper airway secretions:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Any alteration in level of consciousness (eg, stroke, seizure, anesthesia, drug or alcohol intoxication)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dysphagia due to esophageal lesions and motility problems
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Wearing dentures while sleeping [
         <a href="#rid24">
          24
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunocompromising conditions, such as:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diabetes mellitus [
         <a href="#rid25">
          25
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         HIV infection (especially for pneumococcal pneumonia) (see
         <a class="medical medical_review" href="/z/d/html/3716.html" rel="external">
          "Bacterial pulmonary infections in patients with HIV", section on 'Community-acquired pneumonia'
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Solid organ or hematopoietic stem cell transplantation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immunosuppressive medication use (eg, tumor necrosis factor-alpha inhibitors, chemotherapy)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metabolic disorders:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Malnutrition
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Uremia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acidosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lifestyle factors and environmental exposures:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Smoking tobacco
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alcohol consumption
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Opioid use [
         <a href="#rid26">
          26
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Toxic inhalations
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Overcrowding in jails and shelters [
         <a href="#rid27">
          27,28
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Homelessness [
         <a href="#rid29">
          29
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Instrumentation of the respiratory tract (eg, intubation or bronchoscopy) [
         <a href="#rid30">
          30
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Viral respiratory tract infection, especially influenza; influenza can cause viral pneumonia and predispose patients to bacterial pneumonia (see
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis", section on 'Pneumonia'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Combinations of risk factors, such as smoking, congestive heart failure, and COPD, are additive in terms of risk, a concept known as risk factor stacking [
         <a href="#rid29">
          29,31
         </a>
         ].
        </p>
        <p>
         Risk factors for CAP caused by specific pathogens are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7029.html" rel="external">
          "Microbiology, epidemiology, and pathogenesis of
          <i>
           Legionella
          </i>
          infection", section on 'Risk factors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7036.html" rel="external">
          "Pneumonia caused by
          <i>
           Chlamydia pneumoniae
          </i>
          in adults", section on 'Epidemiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6989.html" rel="external">
          "
          <i>
           Mycoplasma pneumoniae
          </i>
          infection in adults", section on 'Epidemiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7013.html" rel="external">
          "Pneumococcal pneumonia in patients requiring hospitalization", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Drugs
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acid-reducing agents
         </strong>
         – Several studies have shown an increased risk of CAP among patients taking gastric acid–suppressive therapy, including proton pump inhibitors and H2 blockers. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/32.html" rel="external">
          "Antiulcer medications: Mechanism of action, pharmacology, and side effects", section on 'Adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Pneumonia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antipsychotic drugs
         </strong>
         – Several studies have shown an association between use of antipsychotic drugs and CAP, although the mechanism remains unclear. In one case-control study, use of antipsychotic drugs was associated with an almost 60 percent increase in the risk of pneumonia among older persons requiring hospitalization [
         <a href="#rid32">
          32
         </a>
         ]. In another case-control study, current use of atypical (odds ratio [OR] 2.61, 95% CI 1.48-4.61) or typical (OR 1.76, 95% CI 1.22-2.53) antipsychotic use was associated with a dose-dependent increased risk for CAP compared with past use [
         <a href="#rid33">
          33
         </a>
         ]. Atypical antipsychotic use was also associated with an increase in the risk of fatal CAP (OR 5.97, 95% CI 1.49-23.98).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ACE inhibitors
         </strong>
         – In a meta-analysis of randomized trials and observational studies, ACE inhibitors were associated with a reduced risk of pneumonia [
         <a href="#rid34">
          34
         </a>
         ]. However, an accompanying editorial noted that this effect was seen only in observational studies (but not in randomized trials), there was a high likelihood of reporting bias, respiratory infection was not a primary outcome of most of the studies, and there was substantial heterogeneity among the studies [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoids
         </strong>
         – Some studies, but not others, have suggested an association between inhaled glucocorticoids for chronic obstructive pulmonary disease and pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/1449.html" rel="external">
          "Role of inhaled glucocorticoid therapy in stable COPD", section on 'Adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids", section on 'Lung infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sedatives
         </strong>
         – Sedatives increase the risk of aspiration pneumonia by reducing consciousness. (See
         <a class="medical medical_review" href="/z/d/html/7024.html" rel="external">
          "Aspiration pneumonia in adults", section on 'Predisposing conditions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          MICROBIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H3246210997">
         <span class="h2">
          Typical versus atypical bacteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bacteria have traditionally been divided into two groups, "typical" and "atypical" agents.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Typical" organisms include
         <em>
          S. pneumoniae
         </em>
         ,
         <em>
          Haemophilus influenzae
         </em>
         ,
         <em>
          Staphylococcus aureus
         </em>
         , group A streptococci,
         <em>
          Moraxella catarrhalis
         </em>
         , anaerobes, and aerobic gram-negative bacteria.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Atypical" pneumonia refers to pneumonia caused by
         <em>
          Legionella
         </em>
         spp,
         <em>
          M. pneumoniae
         </em>
         ,
         <em>
          C.
         </em>
         <em>
          pneumoniae
         </em>
         , and
         <em>
          Chlamydia psittaci
         </em>
         ; although imprecise, we use this term because of its acceptance among clinicians.
        </p>
        <p>
        </p>
        <p>
         In the individual patient, there are no findings from history, physical examination, or routine laboratory studies that allow the clinician to distinguish pneumonia caused by atypical versus typical organisms.
        </p>
        <p class="headingAnchor" id="H310993559">
         <span class="h2">
          Common pathogens
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are more than 100 microbes (bacteria, viruses, fungi, and parasites) that can cause community-acquired pneumonia (CAP). Most cases of CAP in which an organism is identified are caused by one of only four or five microorganisms  (
         <a class="graphic graphic_figure graphicRef139226" href="/z/d/graphic/139226.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef139227" href="/z/d/graphic/139227.html" rel="external">
          figure 2
         </a>
         ), but the distribution of pathogens varies with the clinical setting [
         <a href="#rid36">
          36
         </a>
         ]. A microbiologic diagnosis was confirmed in 38 to 87 percent of cases of CAP in studies that used specialized tests to detect various pathogens [
         <a href="#rid6">
          6,7,37-41
         </a>
         ] but in a lower percentage of cases in studies that did not used specialized tests  (
         <a class="graphic graphic_table graphicRef63248" href="/z/d/graphic/63248.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid42">
          42,43
         </a>
         ]. In clinical practice, an etiologic agent is identified even less frequently. As an example, in a review of 17,435 cases of CAP in the Medicare database for United States emergency departments, an etiologic diagnosis was reported in only 7.6 percent of cases [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         The true prevalence of the various etiologic agents in CAP is uncertain. Studies investigating the etiology of CAP have been performed in different regions, in various patient populations and clinical settings, and using a variety of microbiologic techniques. Because direct culture of infected lung tissue requires invasive techniques, studies primarily use laboratory tests that provide indirect evidence of etiology. These indirect methods include sputum cultures (which may be contaminated with oropharyngeal flora), blood cultures, polymerase chain reaction, urinary antigen tests, and serology. Studies that used serologic testing may have overestimated the incidence of CAP caused by specific pathogens, such as
         <em>
          M. pneumoniae
         </em>
         and
         <em>
          C. pneumoniae
         </em>
         [
         <a href="#rid37">
          37-40,45
         </a>
         ], since positive serologic results may represent recent infection rather than active infection. In addition to the use of indirect methods, interpretation of the results is hampered by the failure to identify an organism in a large proportion of cases and the frequency of mixed infections. Pneumococcal vaccination rates also vary across regions, limiting the extent to which prevalence studies can be pooled or generalized from one region to another.
        </p>
        <p>
         Despite these problems, studies have identified some consistent trends and conclusions regarding the etiology of CAP in adults, which are listed below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          S. pneumoniae
         </em>
         has been the most commonly detected bacterial species in most studies. However, the detection of
         <em>
          S. pneumoniae
         </em>
         from patients with CAP in the United States has declined significantly, likely due in part to the use of pneumococcal vaccines in adults and the universal use of pneumococcal conjugate vaccines in children (leading to herd immunity). (See
         <a class="local">
          'S. pneumoniae'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The coronavirus disease 2019 (COVID-19) pandemic has dramatically changed the epidemiology of CAP. And overall, there is increasing recognition that respiratory viruses are common causes of CAP, either as the sole pathogen or as a coinfecting organism. Using molecular methods, viruses are detected in approximately one-third of cases of CAP in adults in nonepidemic settings. (See
         <a class="local">
          'Viruses'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The "atypical" pathogens (
         <em>
          M. pneumoniae
         </em>
         ,
         <em>
          Legionella
         </em>
         spp, C.
         <em>
          pneumoniae
         </em>
         ,
         <em>
          C.
         </em>
         <em>
          psittaci
         </em>
         ) are not often identified in clinical practice because there are no widely available specific, rapid, or standardized tests for their detection with the exception of
         <em>
          Legionella pneumophila.
         </em>
         Of these,
         <em>
          M. pneumoniae
         </em>
         is the most commonly identified pathogen, especially in pneumonia treated on an ambulatory basis.
         <em>
          Legionella
         </em>
         spp are less common causes of CAP but are important because they can cause severe CAP and can result in outbreaks of pneumonia.
         <em>
          C. pneumoniae
         </em>
         was formerly thought to be common based upon studies that used serologic techniques (which do not distinguish between current and past infection), but more recent studies that used molecular techniques identified
         <em>
          C. pneumoniae
         </em>
         in &lt;1 percent of cases of CAP.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Atypical bacteria, chiefly
         <em>
          M. pneumoniae
         </em>
         and
         <em>
          Legionella
         </em>
         spp, have been detected in approximately 3 to 15 percent of patients with CAP requiring hospitalization using techniques other than serology (eg, molecular techniques,
         <em>
          Legionella
         </em>
         urinary antigen,
         <em>
          Mycoplasma
         </em>
         culture) [
         <a href="#rid6">
          6,7,46
         </a>
         ]. Other studies have detected atypical bacteria in 20 to 30 percent of cases, but these studies may have overestimated the incidence because serologic techniques were used [
         <a href="#rid45">
          45,47,48
         </a>
         ]. In addition, some of the cases may have occurred as part of sporadic outbreaks. (See
         <a class="local">
          'M. pneumoniae'
         </a>
         below and
         <a class="local">
          'C. pneumoniae'
         </a>
         below and
         <a class="local">
          'Legionella'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Staphylococcus aureus
         </em>
         , Enterobacteriaceae, and
         <em>
          Pseudomonas aeruginosa
         </em>
         are important pathogens in selected groups of patients (eg, postinfluenza, prior antimicrobial treatment, or pulmonary comorbidities) [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The etiology of pneumonia in a region is dynamic, as evidenced by the emergence of avian influenza viruses, severe acute respiratory syndrome coronaviruses, and Middle East respiratory syndrome coronavirus (MERS-CoV). (See
         <a class="local">
          'Influenza viruses'
         </a>
         below and
         <a class="local">
          'Middle East respiratory syndrome coronavirus'
         </a>
         below and
         <a class="local">
          'Other viruses'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         The frequency of other etiologic agents, such as
         <em>
          Mycobacterium tuberculosis
         </em>
         ,
         <em>
          C. psittaci
         </em>
         (psittacosis),
         <em>
          Coxiella burnetii
         </em>
         (Q fever),
         <em>
          Francisella tularensis
         </em>
         (tularemia), and endemic fungi (histoplasmosis, coccidioidomycosis, blastomycosis), varies with the epidemiologic setting. (See
         <a class="local">
          'Epidemiologic clues'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1163042006">
         <span class="h3">
          Pathogen detection based on illness severity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most commonly identified pathogens depend in part upon the severity of illness as judged by the site of care (outpatient versus inpatient versus intensive care unit [ICU])  (
         <a class="graphic graphic_table graphicRef72014" href="/z/d/graphic/72014.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid6">
          6,7,37-39,42,45,48,51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4082772435">
         <span class="h4">
          Outpatients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients treated in the outpatient setting, the most frequently detected pathogens are
         <em>
          S. pneumoniae
         </em>
         ,
         <em>
          M. pneumoniae
         </em>
         , and respiratory viruses (eg, influenza, parainfluenza, respiratory syncytial virus [RSV])  (
         <a class="graphic graphic_table graphicRef72014" href="/z/d/graphic/72014.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid39">
          39,48
         </a>
         ].
         <em>
          Legionella pneumoniae
         </em>
         and
         <em>
          H. influenzae
         </em>
         are less common.
        </p>
        <p class="headingAnchor" id="H2412269784">
         <span class="h4">
          Inpatients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients who require hospitalization but not admission to an ICU, the most frequently detected pathogens are
         <em>
          S. pneumoniae
         </em>
         , respiratory viruses (eg, influenza, parainfluenza, RSV, rhinovirus), and, less often,
         <em>
          H. influenzae
         </em>
         ,
         <em>
          M. pneumoniae,
         </em>
         and
         <em>
          Legionella
         </em>
         spp
         <em>
         </em>
         (
         <a class="graphic graphic_table graphicRef72014" href="/z/d/graphic/72014.html" rel="external">
          table 3
         </a>
         )
         <em>
         </em>
         [
         <a href="#rid6">
          6,7,37-39,42,45,51
         </a>
         ]. Among patients who require admission to an ICU,
         <em>
          S. pneumoniae
         </em>
         is the most commonly detected pathogen, but
         <em>
          Legionella
         </em>
         , enteric gram-negative bacilli,
         <em>
          S. aureus
         </em>
         ,
         <em>
          H. influenzae
         </em>
         , and respiratory viruses are also important.
        </p>
        <p>
         In the Etiology of Pneumonia in the Community (EPIC) study, a prospective multicenter population-based active surveillance study conducted by the United States Centers for Disease Control and Prevention (CDC) between 2010 and 2012 that included 2259 adults requiring hospitalization for CAP that used specialized techniques, one or more viruses were detected in 23 percent of cases, bacteria in 11 percent, bacteria and viruses in 3 percent, and fungi or mycobacteria in 1 percent; an etiology was not identified in 62 percent of cases [
         <a href="#rid7">
          7
         </a>
         ]. The most commonly identified organisms were rhinovirus (in 9 percent), influenza virus (in 6 percent), and
         <em>
          S. pneumoniae
         </em>
         (in 5 percent). The incidences of influenza virus and
         <em>
          S. pneumoniae
         </em>
         were nearly five times as high among individuals ≥65 years of age than among younger adults, and the incidence of rhinovirus was nearly 10 times as high among individuals ≥65 years of age than among younger adults. A caveat is that polymerase chain reactions (PCRs) for respiratory viruses was performed from nasopharyngeal or oropharyngeal swabs; positive results may have represented upper respiratory tract infection in some cases. The majority of patients were admitted to a hospital ward; 21 percent required ICU admission.
        </p>
        <p>
         A study of 323 adults with CAP admitted to two tertiary hospitals in the United Kingdom used both bacterial cultures and comprehensive multiplex molecular testing for bacteria and viruses on lower respiratory tract specimens that were collected within 48 hours of admission [
         <a href="#rid6">
          6
         </a>
         ]. Using molecular methods, a pathogen was identified in 87 percent of cases. Culture-based methods detected a pathogen in only 39 percent of cases. Of 127 culture-positive specimens, 125 (98 percent) were also positive for the same bacterial species by PCR.
         <em>
          H. influenzae
         </em>
         and
         <em>
          S. pneumoniae
         </em>
         were the most common agents detected, followed by a wide variety of typical and atypical pathogens. Viruses were present in 30 percent of cases; 82 percent of these were detected in specimens that also tested positive for bacteria. All patients included in this trial were able to produce a mucopurulent sputum specimen, which may have led to an overestimate of diagnostic yield. An additional caveat is that contamination of specimens with upper respiratory tract secretions could cause false-positive results [
         <a href="#rid52">
          52
         </a>
         ]. However, even when a cutoff of ≥100,000 colony forming units/mL was applied to the bacterial species that commonly colonize the oropharynx, 72 percent of patients were considered to have a bacterial cause of CAP, compared with 81 percent when no cutoff was applied [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Epidemiologic clues
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presenting clinical manifestations cannot reliably differentiate between different etiologies, but there are a few epidemiologic and/or clinical clues that can be helpful and must be taken into account when considering the etiology of CAP  (
         <a class="graphic graphic_table graphicRef52808" href="/z/d/graphic/52808.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Know the local epidemiology and the patient's travel history (eg, endemic fungi, such as
         <em>
          Histoplasma
         </em>
         ,
         <em>
          Coccidioides
         </em>
         ,
         <em>
          Blastomyces
         </em>
         , and
         <em>
          Paracoccidioides
         </em>
         spp; hantavirus). (See
         <a class="local">
          'Fungi'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Be aware of national and international outbreaks (eg, influenza [including avian influenza H5N1 and H7N9], SARS, or MERS) in the geographic region that the patient resides in and/or has visited. (See
         <a class="local">
          'Influenza viruses'
         </a>
         below and
         <a class="local">
          'Middle East respiratory syndrome coronavirus'
         </a>
         below and
         <a class="local">
          'Other viruses'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Be aware of local outbreaks of
         <em>
          Legionella
         </em>
         spp,
         <em>
          M.
         </em>
         <em>
          pneumoniae
         </em>
         , or
         <em>
          C. pneumoniae
         </em>
         infections. (See
         <a class="local">
          'Legionella'
         </a>
         below and
         <a class="local">
          'M. pneumoniae'
         </a>
         below and
         <a class="local">
          'C. pneumoniae'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elicit history of specific exposures (eg,
         <em>
          Histoplasma
         </em>
         spp and bat or bird droppings,
         <em>
          C. psittaci
         </em>
         and birds). (See
         <a class="local">
          'Histoplasma capsulatum'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) is an important cause of severe, occasionally necrotizing CAP. Risk factors for CAP caused by MRSA are discussed below. (See
         <a class="local">
          'S. aureus'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MRSA and multidrug-resistant gram-negative bacilli, such as
         <em>
          P. aeruginosa
         </em>
         and extended-spectrum beta-lactamase–producing gram-negative bacilli, should be considered in patients who have certain comorbidities, who have recently received antibiotics, and/or who have had exposure to health care settings. (See
         <a class="local">
          'Gram-negative bacilli'
         </a>
         below and
         <a class="local">
          'S. aureus'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">
          "Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults", section on 'MDR risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who are severely ill with influenza pneumonia should be evaluated for secondary bacterial pneumonia, which is most likely to be caused by
         <em>
          S. pneumoniae
         </em>
         ,
         <em>
          S. aureus
         </em>
         (including MRSA), or group A
         <em>
          Streptococcus
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Never forget
         <em>
          M. tuberculosis
         </em>
         as a cause of pneumonia, particularly in patients who reside in or have visited endemic regions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Pneumocystis jirovecii
         </em>
         (formerly
         <em>
          P. carinii
         </em>
         ) is often forgotten as a cause of CAP now that antiretroviral therapy has resulted in a decrease in the number of cases of
         <em>
          Pneumocystis
         </em>
         pneumonia (PCP) in HIV-infected patients. However, it continues to cause pneumonia in patients with risk factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consider potential agents of bioterrorism that can cause respiratory symptoms. These include
         <em>
          B. anthracis
         </em>
         (inhalation anthrax),
         <em>
          Yersinia pestis
         </em>
         (pneumonic plague),
         <em>
          F. tularensis
         </em>
         (tularemia),
         <em>
          C. burnetii
         </em>
         (Q fever),
         <em>
          Legionella
         </em>
         spp, influenza virus, hantavirus, and ricin  (
         <a class="graphic graphic_table graphicRef56078" href="/z/d/graphic/56078.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'CAP and bioterrorism agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Bacteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         In many studies of patients with CAP, bacteria have been the most commonly detected organisms. The true incidence of these infections is uncertain because of the difficulty in distinguishing colonizing organisms from pathogens.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          <i>
           S. pneumoniae
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          S. pneumoniae
         </em>
         has traditionally been the most common cause of CAP. In the preantibiotic era,
         <em>
          S. pneumoniae
         </em>
         was responsible for &gt;75 percent of cases of pneumonia [
         <a href="#rid2">
          2,53,54
         </a>
         ]. However, more recent studies have isolated the organism in only 5 to 15 percent of cases in the United States [
         <a href="#rid7">
          7,42,55-57
         </a>
         ] but in a higher proportion of cases in some other countries [
         <a href="#rid2">
          2,6,37
         </a>
         ]. Factors that are likely to have contributed to the decline in
         <em>
          S. pneumoniae
         </em>
         as a cause of CAP in the United States include the use of pneumococcal vaccines in adults, the universal use of pneumococcal conjugate vaccines in children (leading to herd immunity), and a reduction in cigarette smoking [
         <a href="#rid2">
          2,58
         </a>
         ].
        </p>
        <p>
         It is important to note that the rate of isolation of
         <em>
          S. pneumoniae
         </em>
         increases when more invasive methods are used for obtaining specimens, such as transtracheal aspiration, which eliminates contaminating oropharyngeal flora; this method was used in the past but is no longer used. It is believed that many culture-negative cases are caused by pneumococcus. One factor arguing for the predominance of
         <em>
          S. pneumoniae
         </em>
         as a cause of CAP is that in patients with CAP who have positive blood cultures, 58 to 81 percent of bloodstream isolates are
         <em>
          S. pneumoniae
         </em>
         [
         <a href="#rid59">
          59,60
         </a>
         ]; however, only 7 to 10 percent of patients with CAP have positive blood cultures [
         <a href="#rid7">
          7,59,60
         </a>
         ]. One group has estimated that, for every case of bacteremic pneumococcal pneumonia, there are at least three additional cases of non-bacteremic pneumococcal pneumonia [
         <a href="#rid61">
          61
         </a>
         ]. The data supporting this conclusion are presented in greater detail separately.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          <i>
           H. influenzae
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nontypeable
         <em>
          H. influenzae
         </em>
         is an important cause of pneumonia in older adults and in patients with underlying pulmonary disease, such as cystic fibrosis and chronic obstructive pulmonary disease (COPD). The clinical features are indistinguishable from CAP caused by other organisms. (See
         <a class="medical medical_review" href="/z/d/html/8048.html" rel="external">
          "Epidemiology, clinical manifestations, diagnosis, and treatment of
          <i>
           Haemophilus influenzae
          </i>
          "
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          <i>
           M. pneumoniae
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          M. pneumoniae
         </em>
         is the most common cause of atypical pneumonia in series from the United States and other parts of the world, accounting for up to 15 percent of cases of pneumonia treated in the ambulatory setting based mostly on serologic methods [
         <a href="#rid48">
          48
         </a>
         ]. However, studies that use serologic techniques may overestimate the incidence. (See
         <a class="local">
          'Common pathogens'
         </a>
         above.)
        </p>
        <p>
         <em>
          M. pneumoniae
         </em>
         is transmitted from person to person by infected respiratory droplets during close contact. Infection rates are highest in school-aged children, military recruits, and college students. Substantial rates of macrolide resistance have been observed in certain regions, such as Asia [
         <a href="#rid62">
          62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6989.html" rel="external">
          "
          <i>
           Mycoplasma pneumoniae
          </i>
          infection in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          <i>
           C. pneumoniae
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of
         <em>
          C. pneumoniae
         </em>
         in adults with CAP has varied in different studies from 0 to 20 percent [
         <a href="#rid37">
          37-39,45
         </a>
         ], although the validity of these data is in question due to problems with diagnostic testing [
         <a href="#rid63">
          63,64
         </a>
         ]. One problem is the use of a serologic test in many studies, which lacks both sensitivity and specificity for
         <em>
          C. pneumoniae
         </em>
         . In addition, positive serologic results may represent either current or past infection. More recent studies that used molecular techniques identified
         <em>
          C. pneumoniae
         </em>
         in &lt;1 percent of cases of CAP [
         <a href="#rid6">
          6,7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">
          "Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults", section on 'Multiplex molecular assays'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7036.html" rel="external">
          "Pneumonia caused by
          <i>
           Chlamydia pneumoniae
          </i>
          in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Transmission of the organism is thought to be person to person and has been implicated in outbreaks of pneumonia in residents of long-term care facilities and military recruits [
         <a href="#rid65">
          65-68
         </a>
         ]. Unlike other respiratory infections, which have peak rates in the winter months,
         <em>
          C. pneumoniae
         </em>
         infection does not vary significantly by season. Pneumonia and bronchitis are the most common respiratory infections associated with
         <em>
          C. pneumoniae
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/7036.html" rel="external">
          "Pneumonia caused by
          <i>
           Chlamydia pneumoniae
          </i>
          in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          <i>
           Legionella
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Legionella
         </em>
         accounts for 1 to 10 percent of cases of CAP.
         <em>
          Legionella
         </em>
         can occur as a sporadic infection or cause outbreaks. Travel-associated legionellosis is becoming more common. In most instances,
         <em>
          Legionella
         </em>
         is transmitted to humans by inhalation of aerosols containing the bacteria. Outbreaks have been associated with exposure to a variety of aerosol-producing devices, including showers, a grocery store mist machine, cooling towers of air conditioning systems, whirlpool spas, and fountains (see
         <a class="medical medical_review" href="/z/d/html/7029.html" rel="external">
          "Microbiology, epidemiology, and pathogenesis of
          <i>
           Legionella
          </i>
          infection"
         </a>
         ). Sporadic legionellosis constitutes the majority of
         <em>
          Legionella
         </em>
         cases and the source for these cases is often unknown. In Connecticut, investigators found an association between residence of cases in proximity to rivers and watersheds [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Gram-negative bacilli
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gram-negative bacilli, especially
         <em>
          Klebsiella pneumoniae
         </em>
         ,
         <em>
          Escherichia coli
         </em>
         ,
         <em>
          Enterobacter
         </em>
         spp,
         <em>
          Serratia
         </em>
         spp,
         <em>
          Proteus
         </em>
         spp,
         <em>
          P. aeruginosa
         </em>
         , and
         <em>
          Acinetobacter
         </em>
         spp, are uncommon causes of CAP except in patients with severe pneumonia requiring admission to an ICU where, as a group, they are among the most commonly isolated organisms after
         <em>
          S. pneumoniae
         </em>
         and in patients with significant underlying disease  (
         <a class="graphic graphic_table graphicRef72014" href="/z/d/graphic/72014.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid70">
          70,71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Likely pathogens'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Klebsiella pneumoniae
         </em>
         –
         <em>
          K. pneumoniae
         </em>
         is responsible for approximately 6 percent of cases of CAP in Asia [
         <a href="#rid45">
          45
         </a>
         ] but is less common in other regions  (
         <a class="graphic graphic_table graphicRef63248" href="/z/d/graphic/63248.html" rel="external">
          table 2
         </a>
         ).
         <em>
          K. pneumoniae
         </em>
         must be considered as a cause of severe CAP in patients who have significant underlying disease, such as COPD, diabetes, and alcohol abuse. In a study of 112 immunocompetent patients with severe CAP, multivariate analysis found
         <em>
          K. pneumoniae
         </em>
         was an independent risk factor for mortality [
         <a href="#rid71">
          71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3122.html" rel="external">
          "Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection", section on 'Community-acquired pneumonia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Pseudomonas aeruginosa
         </em>
         – Risk factors for community-acquired
         <em>
          P. aeruginosa
         </em>
         pneumonia include bronchiectasis (eg, due to cystic fibrosis) and the use of repeated antibiotic courses or prolonged glucocorticoids in patients with other structural lung abnormalities, such as COPD and pulmonary fibrosis [
         <a href="#rid49">
          49,50,72
         </a>
         ]. Immunocompromise (eg, neutropenia, HIV infection, solid organ or hematopoietic stem cell transplantation) and previous hospitalization are other risk factors for
         <em>
          Pseudomonas
         </em>
         pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/3133.html" rel="external">
          "Pseudomonas aeruginosa pneumonia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Acinetobacter
         </em>
         spp –
         <em>
          Acinetobacter
         </em>
         spp are well recognized as pathogens causing nosocomial pneumonia. In addition,
         <em>
          Acinetobacter baumannii
         </em>
         is emerging as a cause of severe CAP with high mortality. Multidrug resistance is an increasing problem with
         <em>
          Acinetobacter
         </em>
         infection. (See
         <a class="medical medical_review" href="/z/d/html/3150.html" rel="external">
          "Acinetobacter infection: Treatment and prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3150.html" rel="external">
          "Acinetobacter infection: Treatment and prevention", section on 'Pneumonia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Moraxella catarrhalis
         </em>
         –
         <em>
          Moraxella
         </em>
         is a gram-negative diplococcus that can cause lower respiratory tract infections in adults with COPD and in immunocompromised persons. In a review of 58 patients with
         <em>
          M. catarrhalis
         </em>
         bacteremia, 70 percent had predisposing factors, such as neutropenia, malignancy, or COPD, either alone or in combination [
         <a href="#rid73">
          73
         </a>
         ]. Many patients with this infection are malnourished. Not infrequently, it is a copathogen [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          <i>
           S. aureus
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         In an international multicenter study of inpatients with CAP, MRSA was detected in 95 of 3193 patients (3 percent) who underwent microbiologic testing within 24 hours of admission, with varying prevalence in different continents and countries [
         <a href="#rid75">
          75
         </a>
         ]. Among all
         <em>
          S. aureus
         </em>
         isolates, 51 percent were MRSA and 49 percent were methicillin-susceptible
         <em>
          S. aureus
         </em>
         (MSSA). In a study in the United States of 2259 inpatients with CAP,
         <em>
          S. aureus
         </em>
         was isolated from 37 patients (1.7 percent), including 15 (0.7 percent) with MRSA and 22 (1 percent) with MSSA [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         <em>
          S. aureus
         </em>
         pneumonia that is community acquired is usually seen in older adults and in younger patients who are recovering from influenza (post-influenza pneumonia) [
         <a href="#rid77">
          77-81
         </a>
         ]. However, the pneumococcus remains the most frequent pathogen in this setting. (See
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis", section on 'Pneumonia'
         </a>
         .)
        </p>
        <p>
         During the 2003 to 2004 influenza season, 17 cases of
         <em>
          S. aureus
         </em>
         CAP were reported to the CDC from nine states; 15 cases were community-associated methicillin-resistant
         <em>
          S. aureus
         </em>
         (CA-MRSA) [
         <a href="#rid78">
          78
         </a>
         ]. All isolates had community-associated genetic characteristics; 12 of 13 available
         <em>
          S. aureus
         </em>
         isolates had the Panton-Valentine leukocidin (PVL) gene. Influenza virus infection was also documented in 12 (71 percent) of cases. All patients were hospitalized and death occurred in five (29 percent); four of the deaths were in patients with MRSA infection. Another outbreak of 10 cases of severe CA-MRSA pneumonia occurred in association with influenza during the 2006 to 2007 influenza season [
         <a href="#rid79">
          79
         </a>
         ]. Six of the patients died.
        </p>
        <p>
         In a study of 627 patients who presented to emergency departments in 12 cities in the United States between the winter of 2006 and the spring of 2007 and who were hospitalized with CAP,
         <em>
          S. aureus
         </em>
         was cultured from the blood and/or respiratory tract in 24 patients (4 percent); of these
         <em>
          S. aureus
         </em>
         infections, 9 (2 percent) were caused by methicillin-susceptible
         <em>
          S. aureus
         </em>
         and 14 (2.4 percent) were caused by methicillin-resistant
         <em>
          S. aureus
         </em>
         [
         <a href="#rid43">
          43
         </a>
         ]. Isolation of MRSA (as compared with any other or no pathogen) was associated with a patient history of MRSA, nursing home admission in the previous year, close contact with someone with a skin infection during the previous month, multiple infiltrates or cavities on chest radiograph, and comatose state, intubation, receipt of pressor agents, or death in the emergency department.
        </p>
        <p>
         CA-MRSA is often associated with severe necrotizing pneumonia [
         <a href="#rid77">
          77-79,82-86
         </a>
         ]. Several studies suggested that the tendency to necrotizing pneumonia may be mediated by PVL, which is typically present in CA-MRSA strains [
         <a href="#rid77">
          77-79,83-85,87-89
         </a>
         ]. However, subsequent reports have disproven the role of PVL as a virulence factor in MRSA pneumonia [
         <a href="#rid90">
          90-94
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h3">
          Other bacteria
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Group A
         </strong>
         <strong>
          <em>
           Streptococcus
          </em>
         </strong>
         – Group A
         <em>
          Streptococcus
         </em>
         (GAS;
         <em>
          S. pyogenes
         </em>
         ) can cause a fulminant pneumonia with early empyema formation even in young, immunocompetent hosts. In a prospective surveillance study for invasive GAS infection, pneumonia accounted for 11 percent of cases with a mortality rate of 38 percent compared with 26 percent for necrotizing fasciitis and 12 percent for the entire cohort of invasive disease [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The largest outbreak of GAS pneumonia in the United States occurred in 2002 among military recruits at the recruiting depot in San Diego [
         <a href="#rid96">
          96,97
         </a>
         ]. Twenty-seven percent of 127 cases of pneumonia were definitely or probably due to GAS, and another 17 percent were coinfected with GAS and another pathogen [
         <a href="#rid96">
          96,97
         </a>
         ]. The epidemic occurred despite prophylaxis against GAS but was ended after the administration of additional prophylaxis [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anaerobes
         </strong>
         – Anaerobic organisms cause the pneumonia that sometimes develops following aspiration and are also involved in necrotizing polymicrobial infections that result in lung abscess. Anaerobic pathogens in pulmonary infections should be suspected when there is putrid sputum or putrid empyema fluid (diagnostic of anaerobes), infection associated with aspiration, which usually results in an infiltrate in a dependent pulmonary segment (superior segment of a lower lobe or posterior segment of an upper lobe), or infection-associated necrosis (abscess or necrotizing pneumonia). Most infections are polymicrobial with predominance of anaerobes (eg,
         <em>
          Bacteroides melaninogenicus
         </em>
         ,
         <em>
          Fusobacterium
         </em>
         spp,
         <em>
          Peptostreptococcus
         </em>
         spp) and/or oral streptococci (eg,
         <em>
          Streptococcus milleri
         </em>
         ). Given the difficulty with obtaining appropriate pretreatment specimens and the tedious microbiology required, most cases are treated empirically. (See
         <a class="medical medical_review" href="/z/d/html/7024.html" rel="external">
          "Aspiration pneumonia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7030.html" rel="external">
          "Lung abscess in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Neisseria meningitidis
          </em>
         </strong>
         <em>
         </em>
         –
         <em>
          N. meningitidis
         </em>
         is an uncommon cause of CAP. Meningococcal pneumonia has no distinguishing clinical features compared to other causes of CAP. However, pneumonia due to
         <em>
          N. meningitidis
         </em>
         should be reported to the health department and prophylaxis given as for meningitis or septicemia. (See
         <a class="medical medical_review" href="/z/d/html/1300.html" rel="external">
          "Clinical manifestations of meningococcal infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Mycobacterium tuberculosis
          </em>
         </strong>
         –
         <em>
          M. tuberculosis
         </em>
         is an important cause of CAP in developing countries and in some regions of the United States [
         <a href="#rid98">
          98,99
         </a>
         ]. Missed diagnosis is common, as illustrated in report from Baltimore in which 16 of 33 patients (48 percent) with culture-confirmed pulmonary tuberculosis (TB) were initially treated for presumed CAP [
         <a href="#rid99">
          99
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7026.html" rel="external">
          "Pulmonary tuberculosis: Clinical manifestations and complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Burkholderia pseudomallei
          </em>
         </strong>
         <em>
          – B. pseudomallei
         </em>
         is an important cause of CAP in endemic regions (South and Southeast Asia, China, and Northern Australia). Occurrence outside of these regions is rare and usually linked to travel. (See
         <a class="medical medical_review" href="/z/d/html/3146.html" rel="external">
          "Melioidosis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other bacteria that can cause CAP include
         <em>
          F. tularensis
         </em>
         (tularemia),
         <em>
          C. burnetii
         </em>
         (Q fever), and
         <em>
          Bacillus anthracis
         </em>
         (anthrax). These microorganisms are described below. (See
         <a class="local">
          'CAP and bioterrorism agents'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Viruses
         </span>
         <span class="headingEndMark">
          —
         </span>
         The frequency of specific viral pathogens varies with the diagnostic studies used for detection [
         <a href="#rid100">
          100
         </a>
         ]. The use of the PCR has increased the diagnostic yield compared with conventional tests, such as viral culture and antigen detection assays [
         <a href="#rid101">
          101-103
         </a>
         ]. As an example, in a randomized trial that included 107 inpatients with CAP, real-time PCR increased the diagnostic yield compared with conventional diagnostic procedures (43 compared with 21 percent) with 26 viral etiologies identified by PCR compared with only 16 by conventional methods [
         <a href="#rid101">
          101
         </a>
         ]. In other studies that used PCR with or without other methods, viruses were detected in up to one-third of cases of CAP in adults [
         <a href="#rid6">
          6,7,37,51,102,104
         </a>
         ]. Since respiratory virus can be present in the upper airways without causing illness, studies using multiplex PCR may overestimate the frequency of viruses as a cause of CAP. Using PCR, nasopharyngeal swabs are positive for respiratory tract viruses in 20 to 30 percent of healthy adults [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
         Influenza remains the clinically most significant viral cause of CAP in adults; other common viral pathogens include RSV, parainfluenza viruses, and adenovirus  (
         <a class="graphic graphic_figure graphicRef139226" href="/z/d/graphic/139226.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef139227" href="/z/d/graphic/139227.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid102">
          102
         </a>
         ]. Other viruses that have been detected in patients with CAP include rhinoviruses, coronaviruses, and human metapneumovirus (hMPV) [
         <a href="#rid102">
          102
         </a>
         ]. However, in a study that used multiplex PCR, in 30 of 32 patients in whom rhinovirus or a coronavirus was implicated, another organism was also identified [
         <a href="#rid106">
          106
         </a>
         ]. A possible reason for this is that rhinovirus and coronavirus were not causing the pneumonia but impairing upper airway defenses so that pathogens can establish themselves in the lower respiratory tract. In another study, bacterial coinfection was associated with approximately 40 percent of viral respiratory tract infections requiring hospitalization [
         <a href="#rid107">
          107
         </a>
         ]. In a separate study, the rate of mixed viral-bacterial infection was approximately 20 percent; such mixed infections have been found to be associated with more severe CAP and longer hospitalization than CAP caused by bacteria alone [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
         Although viruses are commonly found in the nasopharynx of adults with CAP, it is often unclear whether these viruses are the sole agents causing CAP. In addition to possibly predisposing patients to infections with other organisms, the presence of a respiratory virus may also represent prolonged shedding (especially in immunocompromised hosts), upper respiratory tract infection, or colonization.
        </p>
        <p>
         However, some studies have suggested that viruses like rhinovirus are likely to play a pathogenic role in CAP in adults. As an example, one study evaluated whether viruses are detected in the nasopharynx by PCR more commonly in patients with pneumonia than in asymptomatic individuals sampled at the same time and in the same geographic area [
         <a href="#rid109">
          109
         </a>
         ]. Viruses were detected rarely in asymptomatic adults but frequently in adults with CAP (2.1 versus 24.5 percent). Viruses were detected more often in both asymptomatic children (24.4 percent) and children with CAP (68.8 percent) compared with adults. Detection of influenza, RSV, and hMPV were rare in asymptomatic adults and children. Associations of rhinovirus and adenovirus with CAP varied with age. Asymptomatic rhinovirus detection declined with increasing age. This led to a strong association of rhinovirus with CAP in adults, a more modest association in older children, and no association in younger children. In children, RSV and hMPV were highly associated with CAP. Adenovirus in the nasopharynx was only associated with CAP in children &lt;2 years of age but not in older children.
        </p>
        <p>
         In a study of 259 patients with a pneumonia syndrome, 44 viruses were detected in 42 patients: 26 (16.2 percent) had rhinovirus, 7 had coronavirus, 4 had parainfluenza virus, 3 had RSV, 1 had hMPV, and 1 had influenza [
         <a href="#rid55">
          55
         </a>
         ]. A virus was the only pathogen detected in 30; 3 of 30 patients had clinical characteristics suggestive of bacterial pneumonia. The procalcitonin level was 0.81, significantly lower than in patients with bacterial infection. In 28 of 42 patients (66.6 percent), there was reasonable evidence that the viral pathogen detected in the nasopharynx did indeed cause the pneumonia.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h3">
          Influenza viruses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Influenza A or B viruses cause an acute respiratory illness that occurs in outbreaks and epidemics worldwide, mainly in the winter season. Avian influenza viruses (eg, H5N1 and H7N9 avian influenza) have emerged to cause disease in humans. (See
         <a class="medical medical_review" href="/z/d/html/7006.html" rel="external">
          "Influenza: Epidemiology and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7002.html" rel="external">
          "Avian influenza: Epidemiology and transmission"
         </a>
         .)
        </p>
        <p>
         Influenza viruses can cause pneumonia, although they are far more likely to cause upper respiratory tract infection and to predispose to secondary pulmonary infection by bacteria. (See
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis", section on 'Pneumonia'
         </a>
         .)
        </p>
        <p>
         Primary influenza pneumonia occurs when influenza virus infection directly involves the lung, typically producing a severe pneumonia. Influenza pneumonia occurs most frequently in certain groups of patients with underlying chronic illnesses who are classified as "high risk" for this infection  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
         Patients who are severely ill with influenza should be evaluated for a secondary bacterial pneumonia, which is most likely to be caused by
         <em>
          S. pneumoniae
         </em>
         ,
         <em>
          S. aureus
         </em>
         (including MRSA), or group A streptococci. (See
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         The first association of avian influenza H5N1 with clinical respiratory disease occurred in Hong Kong in 1997 when 18 human cases occurred during a poultry outbreak of highly pathogenic H5N1 influenza in live bird markets. The clinical features of avian influenza are variable, being determined in part by the strain. In the 1997 outbreak, 58 percent of patients had pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/7002.html" rel="external">
          "Avian influenza: Epidemiology and transmission"
         </a>
         .)
        </p>
        <p>
         Another avian influenza virus, H7N9, emerged in China in 2013 and has caused severe pneumonia in some patients. (See
         <a class="medical medical_review" href="/z/d/html/7002.html" rel="external">
          "Avian influenza: Epidemiology and transmission", section on 'Avian influenza H7N9'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1911877979">
         <span class="h3">
          Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
         </span>
         <span class="headingEndMark">
          —
         </span>
         COVID-19, the disease caused by SARS-CoV-2, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">
          "COVID-19: Epidemiology, virology, and prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h3">
          Parainfluenza viruses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parainfluenza viruses are important respiratory pathogens in immunocompromised adults, causing potentially life-threatening lower respiratory tract infections. (See
         <a class="medical medical_review" href="/z/d/html/7009.html" rel="external">
          "Parainfluenza viruses in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h3">
          Respiratory syncytial virus
         </span>
         <span class="headingEndMark">
          —
         </span>
         RSV causes acute respiratory tract illness in persons of all ages. Traditionally a viral pathogen of children, RSV can also cause CAP in adults and can be particularly severe in older adults and immunocompromised individuals (eg, hematopoietic cell transplant recipients). (See
         <a class="medical medical_review" href="/z/d/html/5994.html" rel="external">
          "Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h3">
          Adenovirus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adenovirus pneumonia was first described among military recruits in whom it causes an "atypical pneumonia." The usual symptoms are fever, malaise, and cough (often with substernal discomfort). Increased peribronchial markings with patchy alveolar infiltrates are found on chest radiography. Pneumonia occasionally results in fatalities. (See
         <a class="medical medical_review" href="/z/d/html/8339.html" rel="external">
          "Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h3">
          Human metapneumovirus
         </span>
         <span class="headingEndMark">
          —
         </span>
         HMPV was first described in 2001 in the Netherlands. HMPV can cause upper and lower respiratory tract infection in patients of all age groups, but symptomatic disease most often occurs in young children or older adults. It is an emerging pathogen as a cause of CAP in adults. (See
         <a class="medical medical_review" href="/z/d/html/8311.html" rel="external">
          "Human metapneumovirus infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H326992777">
         <span class="h3">
          Middle East respiratory syndrome coronavirus
         </span>
         <span class="headingEndMark">
          —
         </span>
         A novel coronavirus, Middle East respiratory syndrome coronavirus, causing severe respiratory illness, emerged in 2012 in Saudi Arabia. Additional cases and clusters of MERS-CoV infections have been detected subsequently in Saudi Arabia, other Arabian Peninsula countries, and other countries. MERS should be considered in patients who have traveled to the Arabian Peninsula within 14 days of presentation. (See
         <a class="medical medical_review" href="/z/d/html/89705.html" rel="external">
          "Middle East respiratory syndrome coronavirus: Virology, pathogenesis, and epidemiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106589.html" rel="external">
          "Middle East respiratory syndrome coronavirus: Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Although most clusters of MERS have been characterized by limited human-to-human transmission, an outbreak of MERS in South Korea in 2015 was associated with superspreading events. Superspreading events are outbreaks in which specific individuals are responsible for a disproportionately large number of transmission events [
         <a href="#rid110">
          110
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/89705.html" rel="external">
          "Middle East respiratory syndrome coronavirus: Virology, pathogenesis, and epidemiology", section on 'Human-to-human transmission'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H374975063">
         <span class="h3">
          Rhinovirus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rhinoviruses are among the most common pathogens that affect humans and are implicated in 30 to 50 percent of acute respiratory tract infections [
         <a href="#rid111">
          111
         </a>
         ]. The advent of multiplex PCR for the etiologic diagnosis of CAP has led to the current prominence of rhinoviruses in the CAP field. As an example, a 2005 study showed that inclusion of PCR on nasopharyngeal and oropharyngeal swabs of patients with CAP improved the diagnostic yield by 16 percent [
         <a href="#rid106">
          106
         </a>
         ]. The most common virus detected was rhinovirus, in 18 of 105 patients (17 percent).
        </p>
        <p>
         The evidence is accumulating that rhinovirus is likely to play a role in CAP in adults. Nevertheless, some experts have questioned the role of rhinoviruses in the pathogenesis of pneumonia [
         <a href="#rid111">
          111,112
         </a>
         ], arguing that the frequency of rhinovirus infections in the population makes assessment of causal role in pneumonia difficult [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
         In the EPIC study, a prospective multicenter population-based active surveillance study of 2259 adults requiring hospitalization for CAP, rhinovirus was the most commonly identified organism (in 9 percent) [
         <a href="#rid7">
          7
         </a>
         ]. The incidence of rhinovirus was nearly 10 times as high among CAP patients ≥65 years of age than among younger CAP patients. A caveat is that PCR for rhinovirus was performed from nasopharyngeal or oropharyngeal swabs; positive results may have represented upper respiratory tract infection in some cases. Nevertheless, a related study suggested that rhinovirus is strongly associated with CAP in adults (but not in children) [
         <a href="#rid109">
          109
         </a>
         ]. Rhinovirus was detected in 21 of 192 adults with CAP (10.9 percent) but in only 2 of 238 asymptomatic adults (0.8 percent). (See
         <a class="local">
          'Viruses'
         </a>
         above.)
        </p>
        <p>
         In a single-center study in Finland conducted from June 2008 to May 2012, three nasopharyngeal swabs and bronchoalveolar lavage fluid were obtained from adults with CAP who were started on mechanical ventilation during the first 48 hours following ICU admission [
         <a href="#rid103">
          103
         </a>
         ]. Of the 49 patients studied, a bacterium was detected in 43 percent and a virus in 49 percent; in 10 percent of patients, a virus was the only pathogen detected. Rhinoviruses were found in 31 percent of patients
         <strong>
          .
         </strong>
        </p>
        <p class="headingAnchor" id="H3425055843">
         <span class="h3">
          Other viruses
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe acute respiratory syndrome
         </strong>
         – In November 2002, an outbreak of SARS started in Guangdong Province in southern China and spread worldwide, affecting more than 8000 persons. SARS was due to a novel coronavirus that jumped the species barrier from civet cats to man. The case-fatality rate of the 2003 Hong Kong outbreak was 11 percent, but higher mortality was seen in older adults (≥60 years of age) and pregnant women. Superspreading events, which are outbreaks in which specific individuals are responsible for a disproportionately large number of transmission events, likely contributed to the SARS outbreak [
         <a href="#rid110">
          110
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3027.html" rel="external">
          "Severe acute respiratory syndrome (SARS)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3027.html" rel="external">
          "Severe acute respiratory syndrome (SARS)", section on 'Transmission'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other coronaviruses
         </strong>
         – Human coronaviruses were first described in association with respiratory infections in 1935 but were ignored until the advent of SARS. HCoV-229E and HCoV-OC43 caused upper and lower respiratory tract infections prior to the SARS outbreaks. Since that time, human coronaviruses HCoV-NL63 and CoV-HKU1 have been identified as additional etiologic agents in CAP.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HCoV-NL63 was recovered from 19 of 525 (3.6 percent) of respiratory specimens collected from laboratories across Canada in 2001 and 2002 [
         <a href="#rid113">
          113
         </a>
         ], primarily causing infections of the upper respiratory tract. In contrast, CoV-HKU1 accounted for 2.4 percent (10 of 418) of CAP cases in Hong Kong [
         <a href="#rid114">
          114
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8298.html" rel="external">
          "Coronaviruses"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hantavirus
         </strong>
         – In May 1993, an outbreak of severe respiratory illness caused by a previously unknown virus, hantavirus, occurred in the southwestern United States. The illness was preceded by prodromal flu-like symptoms, followed by noncardiogenic pulmonary edema. The virus accounting for the initial cases, Sin Nombre virus, is spread to humans from infected mice. Subsequently, other hantaviruses have been found to cause hantavirus pulmonary syndrome, and the disease has been described in other parts of the United States, western Canada, and South America. It is important to recognize that hantavirus does not cause pneumonia but instead causes an acute respiratory distress syndrome (ARDS)-like picture due to the host response to this virus. (See
         <a class="medical medical_review" href="/z/d/html/8307.html" rel="external">
          "Epidemiology and diagnosis of hantavirus infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8321.html" rel="external">
          "Hantavirus cardiopulmonary syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Varicella
         </strong>
         – Varicella pneumonia is the most frequent complication of varicella infection in normal healthy adults, with a reported incidence of about 1 in 400 cases. The case-fatality rate is between 10 and 30 percent. (See
         <a class="medical medical_review" href="/z/d/html/8284.html" rel="external">
          "Clinical features of varicella-zoster virus infection: Chickenpox"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H35">
         <span class="h2">
          Fungi
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fungal infection is an unusual cause of CAP in immunocompetent patients, but certain fungi (eg,
         <em>
          Histoplasma capsulatum
         </em>
         ,
         <em>
          Coccidioides
         </em>
         spp,
         <em>
          Blastomyces dermatitidis
         </em>
         ) can cause pneumonia in immunocompetent or immunocompromised patients who reside in or have visited endemic areas. The specific epidemiology of some fungal infections is therefore important as a diagnostic clue. Fungal infection is more common in immunocompromised patients, particularly those with neutropenia, those receiving chronic immunosuppressive therapy (eg, organ transplant recipients), and those infected with HIV.
        </p>
        <p>
         A retrospective study examined the microbiologic etiology of 94 cases of community-acquired pulmonary fungal infection hospitalized in Taiwan [
         <a href="#rid115">
          115
         </a>
         ]. The criteria for diagnosis were a lung lesion on chest radiographs and either the presence or isolation of fungi from a tissue biopsy, pleural effusion, or blood. The most frequently isolated fungi were
         <em>
          Aspergillus
         </em>
         species (56 percent), followed by
         <em>
          Cryptococcus
         </em>
         species (31 percent), and
         <em>
          Candida
         </em>
         species (4 percent).
        </p>
        <p class="headingAnchor" id="H36">
         <span class="h3">
          <i>
           Cryptococcus
          </i>
          spp
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Cryptococcus
         </em>
         organisms are found in the soil throughout the world, and a significant percent of the population has most likely been exposed to these organisms. Primary infections occur in both immunocompetent and immunocompromised persons. In immunocompetent individuals, primary infections are most commonly asymptomatic and usually discovered as an incidental finding on chest radiograph. In contrast, cryptococcal pneumonia in immunocompromised patients is usually symptomatic with the most common signs and symptoms being cough, fever, and dyspnea. (See
         <a class="medical medical_review" href="/z/d/html/2448.html" rel="external">
          "Microbiology and epidemiology of Cryptococcus neoformans infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2421.html" rel="external">
          "Cryptococcus neoformans infection outside the central nervous system"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H37">
         <span class="h3">
          <i>
           Histoplasma capsulatum
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          H. capsulatum
         </em>
         is found worldwide; within the United States, infection is most common in the Midwestern states located in the Ohio and Mississippi River Valleys.
         <em>
          H. capsulatum
         </em>
         proliferates best in soil contaminated with bird or bat droppings. Less than 5 percent of exposed individuals develop symptomatic disease after a low-level exposure. However, the majority of patients develop symptomatic infection following more extensive exposure, as occurs with activities that disturb heavily contaminated soil or areas with large amounts of bird or bat droppings.
        </p>
        <p>
         Symptomatic patients with acute histoplasmosis generally present with a flu-like illness with pulmonary complaints and radiographic abnormalities, including bronchopneumonia or signs of interstitial pneumonitis. (See
         <a class="medical medical_review" href="/z/d/html/2450.html" rel="external">
          "Pathogenesis and clinical features of pulmonary histoplasmosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H38">
         <span class="h3">
          <i>
           Coccidioides
          </i>
          spp
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coccidioidomycosis is the infection caused by the dimorphic fungi of the genus
         <em>
          Coccidioides
         </em>
         (
         <em>
          C. immitis
         </em>
         and
         <em>
          C. posadasii
         </em>
         ). These fungi are endemic to certain deserts of the Western Hemisphere, including southern Arizona, central California, southwestern New Mexico, and west Texas in the United States. They are also found in parts of Mexico and Central and South America. (See
         <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">
          "Primary pulmonary coccidioidal infection", section on 'Epidemiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">
          "Primary pulmonary coccidioidal infection", section on 'Microbiology'
         </a>
         .)
        </p>
        <p>
         A prospective observational study of 55 adults with CAP in Arizona found serologic evidence for coccidioidomycosis (valley fever) as the etiologic agent in 16 patients (29 percent) [
         <a href="#rid116">
          116
         </a>
         ]. This study suggests that valley fever is a common cause of CAP after exposure in a disease-endemic region and that patients exposed in these regions that develop CAP should undergo laboratory evaluation for this organism.
        </p>
        <p>
         The most common presenting symptoms of primary coccidioidal infection are chest pain, cough, and fever. Although initial infections usually have a respiratory component, chest radiographs are unremarkable in up to one-half of all patients. Common radiographic abnormalities include unilateral infiltrate and ipsilateral hilar adenopathy. (See
         <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">
          "Primary pulmonary coccidioidal infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H39">
         <span class="h3">
          Other fungi
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other fungi that can cause CAP include
         <em>
          Aspergillus
         </em>
         spp and
         <em>
          Pneumocystis jirovecii
         </em>
         (formerly
         <em>
          P. carinii
         </em>
         ). Infection with these fungi occurs primarily in the setting of immunosuppression. Pulmonary aspergillosis is particularly associated with severe neutropenia, while
         <em>
          P. jirovecii
         </em>
         is particularly associated with HIV infection and other defects in cell-mediated immunity. (See
         <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">
          "Epidemiology and clinical manifestations of invasive aspergillosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3704.html" rel="external">
          "Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1406.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV"
         </a>
         .)
        </p>
        <p>
         <em>
          B. dermatitidis
         </em>
         can cause pneumonia in both immunocompetent and immunocompromised hosts. (See
         <a class="medical medical_review" href="/z/d/html/2437.html" rel="external">
          "Clinical manifestations and diagnosis of blastomycosis", section on 'Pulmonary involvement'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2458.html" rel="external">
          "Mycology, pathogenesis, and epidemiology of blastomycosis", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H40">
         <span class="h2">
          Mixed infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of more than one causative microorganism in CAP is difficult to establish. A prospective study of 1511 consecutive hospitalized patients examined the incidence of mixed respiratory pathogens in patients with CAP [
         <a href="#rid117">
          117
         </a>
         ]. Microbiologic evaluation included sputum and blood cultures (and pleural fluid, transbronchial aspirates, protected specimen brush, and bronchial alveolar lavage when available), paired serologies (for influenza, parainfluenza, respiratory syncytial, and adenoviruses and
         <em>
          C. pneumoniae
         </em>
         ,
         <em>
          M. pneumoniae
         </em>
         ,
         <em>
          L. pneumophila
         </em>
         , and
         <em>
          C. burnetii
         </em>
         ), and urine antigen (for
         <em>
          S. pneumoniae
         </em>
         and
         <em>
          L. pneumophila
         </em>
         ). Of 610 patients in whom an etiology was identified, 82 (13 percent) had more than one microorganism.
         <em>
          S. pneumoniae
         </em>
         was identified in 44 of 82 mixed infections (54 percent).
        </p>
        <p>
         The clinical importance of mixed infections on outcome is difficult to assess, although there is a suggestion that patients with mixed infections have a more severe illness as illustrated in a prospective study of 493 patients with CAP in whom an extensive microbiologic workup was performed [
         <a href="#rid118">
          118
         </a>
         ]. Compared with patients with monomicrobial pneumonia, patients with mixed pneumonia were more likely to have complications of the pneumonia (39.3 versus 18.6 percent); however, they were also more likely to have an underlying comorbid illness (64 versus 45 percent).
        </p>
        <p class="headingAnchor" id="H41">
         <span class="h2">
          CAP and bioterrorism agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several biological agents may be used for bioterrorism and can cause a CAP syndrome. In the event of a possible bioterrorist event, local emergency response systems should be activated by dialing 911 in the United States or equivalent emergency telephone numbers in other countries. Local and state public health authorities should also be notified immediately. In addition, in the United States, the local Federal Bureau of Investigation office should be contacted promptly. (See
         <a class="medical medical_review" href="/z/d/html/2735.html" rel="external">
          "Identifying and managing casualties of biological terrorism", section on 'Public health notification'
         </a>
         .)
        </p>
        <p>
         Bioterrorism agents that can cause CAP include
         <em>
          B. anthracis
         </em>
         (inhalation anthrax),
         <em>
          Yersinia pestis
         </em>
         (pneumonic plague),
         <em>
          F. tularensis
         </em>
         (tularemia),
         <em>
          C. burnetii
         </em>
         (Q fever),
         <em>
          Legionella
         </em>
         spp, influenza virus, and hantavirus  (
         <a class="graphic graphic_table graphicRef56078" href="/z/d/graphic/56078.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid119">
          119
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Bacillus anthracis
          </em>
         </strong>
         <strong>
          (anthrax)
         </strong>
         – On October 2, 2001, a 63-year-old male from Florida became the first case of inhalation anthrax in the United States since 1968 and was the first due to an act of biological terrorism. Anthrax was deliberately spread through the postal system by sending letters with a powder containing
         <em>
          B. anthracis
         </em>
         , a gram-positive bacillus that forms spores. Two of the 22 persons infected in the postal attack developed inhalational anthrax. (See
         <a class="medical medical_review" href="/z/d/html/5506.html" rel="external">
          "Microbiology, pathogenesis, and epidemiology of anthrax"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Inhalation anthrax is the deadliest form of the disease. The incubation period following exposure is one to six days. The classic chest radiograph findings are mediastinal widening with pleural effusions. A World Health Organization expert committee estimated that if 50 kg of anthrax was released over an urban population of five million, there would be 250,000 casualties, 100,000 of whom would be expected to die without treatment [
         <a href="#rid120">
          120
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5533.html" rel="external">
          "Clinical manifestations and diagnosis of anthrax"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Yersinia pestis
          </em>
         </strong>
         <strong>
          (plague)
         </strong>
         – Biological weapons programs in the United States and the Soviet Union following World War II developed techniques for aerosolizing
         <em>
          Y. pestis
         </em>
         , the agent of plague. The hypothetical intentional release of aerosolized plague would cause widespread illness; the case-fatality rate for primary pneumonic plague is close to 100 percent if treatment is not initiated within 24 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The time to onset of symptoms following exposure is two to three days. The most common chest radiograph findings are bilateral infiltrates, often with pleural effusions. (See
         <a class="medical medical_review" href="/z/d/html/3131.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of plague (
          <i>
           Yersinia pestis
          </i>
          infection)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Francisella tularensis
          </em>
         </strong>
         <strong>
          (tularemia)
         </strong>
         – Tularemia is caused by the gram-negative bacilli,
         <em>
          F. tularensis
         </em>
         . During the 1950s and 1960s, both the United States and the Soviet Union biological weapons program developed aerosolized
         <em>
          F. tularensis
         </em>
         . It has been estimated that dispersal of 50 kg of virulent
         <em>
          F. tularensis
         </em>
         over a metropolitan area with five million people would result in 250,000 incapacitating casualties, including 19,000 deaths [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Tularemia has a longer incubation period than either inhalation anthrax or plague. The classic chest radiographic findings are bilateral infiltrates with hilar adenopathy. (See
         <a class="medical medical_review" href="/z/d/html/3141.html" rel="external">
          "Tularemia: Clinical manifestations, diagnosis, treatment, and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           C. burnetii
          </em>
         </strong>
         <strong>
          (Q fever)
         </strong>
         –
         <em>
          C. burnetii
         </em>
         is the etiologic agent of Q fever and is a CDC category B biological agent. As a biological warfare agent,
         <em>
          C. burnetii
         </em>
         can be easily dispersed as an aerosol with a high infectivity rate and pneumonia as the major manifestation. Further information regarding Q fever can be found on the United States
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fqfever%2Fhealthcare-providers%2Findex.html&amp;token=JesNUNaJCNOJVQWCCy%2BywE9kqc5IU385wxveHccQyRSfy2l%2Fi1Nn583eHrl95FWC%2BYgb2SZ9DkIEVM4LBxkNAg%3D%3D&amp;TOPIC_ID=6990" target="_blank">
          Centers for Disease Control and Prevention website
         </a>
         [
         <a href="#rid122">
          122,123
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Ricin is a toxin naturally found in castor beans that could be used as an agent of bioterrorism. Although ricin does not cause CAP, inhalational ricin may cause respiratory distress, fever, cough, and pulmonary edema. (See
         <a class="medical medical_review" href="/z/d/html/2735.html" rel="external">
          "Identifying and managing casualties of biological terrorism", section on 'Toxins of concern'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H46">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16993.html" rel="external">
          "Patient education: Community-acquired pneumonia in adults (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/4002.html" rel="external">
          "Patient education: Pneumonia in adults (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H456952782">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Community-acquired pneumonia (CAP) is a common and potentially serious illness. It is associated with considerable morbidity and mortality, particularly in older adult patients and those with significant comorbidities. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The overall incidence of CAP in adults is estimated at approximately 16 to 23 cases per 1000 persons per year; the rate rises with age. There is seasonal variation, with more cases occurring during the winter months. The rates of pneumonia are higher for men than for women and for Black persons compared with White persons. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The lungs are constantly exposed to particulate material and microbes that are present in the upper airways and, by microaspiration, enter the lower respiratory tract. Contrary to longstanding belief, the lower respiratory tract is not sterile. Healthy lower airways contain some bacterial species that are also found in the upper respiratory tract, such as
         <em>
          Prevotella
         </em>
         spp,
         <em>
          Veillonella
         </em>
         spp, and
         <em>
          Streptococcus
         </em>
         spp. The development of CAP indicates either a defect in host defenses, exposure to a particularly virulent microorganism, or an overwhelming inoculum. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In addition to microbial virulence factors, diseases and conditions in the host may lead to impairment of pulmonary defense and increased risk of CAP  (
         <a class="graphic graphic_table graphicRef52808" href="/z/d/graphic/52808.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Predisposing host conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presenting clinical manifestations cannot reliably differentiate between different etiologies, but there are a few epidemiologic and/or clinical clues that can be helpful and must be taken into account when considering the etiology of CAP  (
         <a class="graphic graphic_table graphicRef52808" href="/z/d/graphic/52808.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Epidemiologic clues'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are more than 100 microbes (bacteria, viruses, fungi, and parasites) that can cause CAP. Most cases of pneumonia are caused by one of only four or five microorganisms  (
         <a class="graphic graphic_figure graphicRef139226" href="/z/d/graphic/139226.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef139227" href="/z/d/graphic/139227.html" rel="external">
          figure 2
         </a>
         ). The most commonly identified pathogens depend in part upon the severity of illness as judged by the site of care (outpatient versus inpatient versus intensive care unit)  (
         <a class="graphic graphic_table graphicRef72014" href="/z/d/graphic/72014.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In many studies of patients with CAP, bacteria have been the most commonly detected organisms. The true incidence of these infections is uncertain because of the difficulty in distinguishing colonizing organisms from pathogens.
         <em>
          S. pneumoniae
         </em>
         is the most commonly identified bacterial cause of CAP. However, it has decreased markedly due to pneumococcal vaccines  (
         <a class="graphic graphic_table graphicRef72014" href="/z/d/graphic/72014.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef63248" href="/z/d/graphic/63248.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Bacteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Using molecular methods, viruses are detected in approximately one-third of cases of CAP in adults. Influenza is the most significant viral cause of CAP in adults. SARS-CoV-2 is an important cause during the pandemic. Mixed viral-bacterial infection is relatively common. (See
         <a class="local">
          'Viruses'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fungal infection is an unusual cause of CAP in the immunocompetent patient, but certain fungi (eg,
         <em>
          Histoplasma capsulatum
         </em>
         ,
         <em>
          Coccidioides
         </em>
         spp) can cause pneumonia in immunocompetent or immunocompromised patients who reside in or have visited endemic areas. The specific epidemiology of some fungal infections is therefore important as a diagnostic clue. Fungal infection is more common in immunocompromised patients, particularly those with neutropenia, those receiving chronic immunosuppressive therapy (eg, organ transplant recipients), and those infected with HIV. (See
         <a class="local">
          'Fungi'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H133679872">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           File TM. Community-acquired pneumonia. Lancet 2003; 362:1991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014; 371:1619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marrie TJ, Huang JQ. Epidemiology of community-acquired pneumonia in Edmonton, Alberta: an emergency department-based study. Can Respir J 2005; 12:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramirez JA, Wiemken TL, Peyrani P, et al. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis 2017; 65:1806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis 2016; 62:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015; 373:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010; 122:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep 2008; 56:1.
          </a>
         </li>
         <li class="breakAll">
          Medicare.gov - Hospital Compare. https://www.medicare.gov/hospitalcompare/search.html (Accessed on April 19, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold FW, Wiemken TL, Peyrani P, et al. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med 2013; 107:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 2014; 58:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gross AE, Van Schooneveld TC, Olsen KM, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother 2014; 58:5262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yap V, Datta D, Metersky ML. Is the present definition of health care-associated pneumonia the best way to define risk of infection with antibiotic-resistant pathogens? Infect Dis Clin North Am 2013; 27:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez A, Amaro R, Polverino E. Does health care associated pneumonia really exist? Eur J Intern Med 2012; 23:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickson RP, Erb-Downward JR, Martinez FJ, Huffnagle GB. The Microbiome and the Respiratory Tract. Annu Rev Physiol 2016; 78:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wunderink RG, Waterer GW. Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infect Dis Clin North Am 2004; 18:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strieter RM, Belperio JA, Keane MP. Host innate defenses in the lung: the role of cytokines. Curr Opin Infect Dis 2003; 16:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason CM, Nelson S. Pulmonary host defenses and factors predisposing to lung infection. Clin Chest Med 2005; 26:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almirall J, Bolíbar I, Balanzó X, González CA. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999; 13:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iinuma T, Arai Y, Abe Y, et al. Denture wearing during sleep doubles the risk of pneumonia in the very elderly. J Dent Res 2015; 94:28S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen AV, Faurholt-Jepsen D, Egelund GB, et al. Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study. Clin Infect Dis 2017; 65:2091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edelman EJ, Gordon KS, Crothers K, et al. Association of Prescribed Opioids With Increased Risk of Community-Acquired Pneumonia Among Patients With and Without HIV. JAMA Intern Med 2019; 179:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoge CW, Reichler MR, Dominguez EA, et al. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N Engl J Med 1994; 331:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men's shelters. Chest 1991; 99:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plevneshi A, Svoboda T, Armstrong I, et al. Population-based surveillance for invasive pneumococcal disease in homeless adults in Toronto. PLoS One 2009; 4:e7255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardner JG, Rueda AM, Musher DM. Acute Onset of Pneumococcal Pneumonia Following Instrumentation of the Respiratory Tract. Open Forum Infect Dis 2018; 5:ofy047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curcio D, Cané A, Isturiz R. Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence. Int J Infect Dis 2015; 37:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knol W, van Marum RJ, Jansen PA, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008; 56:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trifirò G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med 2010; 152:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ 2012; 345:e4260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes RA. Pneumonia and ACE inhibitors--and cough. BMJ 2012; 345:e4566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Abers MS, Bartlett JG. Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus. Clin Infect Dis 2017; 65:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shibli F, Chazan B, Nitzan O, et al. Etiology of community-acquired pneumonia in hospitalized patients in northern Israel. Isr Med Assoc J 2010; 12:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cillóniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shindo Y, Ito R, Kobayashi D, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 2013; 188:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjarnason A, Westin J, Lindh M, et al. Incidence, Etiology, and Outcomes of Community-Acquired Pneumonia: A Population-Based Study. Open Forum Infect Dis 2018; 5:ofy010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Restrepo MI, Mortensen EM, Velez JA, et al. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 2008; 133:610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis 2012; 54:1126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis 2011; 52 Suppl 4:S296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song JH, Oh WS, Kang CI, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008; 31:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           File TM Jr, Rewerska B, Vucinić-Mihailović V, et al. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. Clin Infect Dis 2016; 63:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 175:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005; 99:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162:1849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Restrepo MI, Babu BL, Reyes LF, et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J 2018; 52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman D, Shimoni A, Shemer-Avni Y, et al. Respiratory viruses in adults with community-acquired pneumonia. Chest 2010; 138:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain S, Pavia AT. Editorial Commentary: The Modern Quest for the "Holy Grail" of Pneumonia Etiology. Clin Infect Dis 2016; 62:826.
          </a>
         </li>
         <li class="breakAll">
          Heffron R. Pneumonia, with special reference to pneumococcus lobar pneumonia, Harvard University Press, Cambridge, MA 1939.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bullowa JGM, Sommers M, Turner E. The reliability of sputum typing and its relation to serum therapy. J Am Med Assoc 1935; 105:1512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Roig IL, Cazares G, et al. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect 2013; 67:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. J Infect Dis 2013; 208:1813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM. Editorial Commentary: Quantitative Molecular Approach to Diagnosing Pneumonia. Clin Infect Dis 2016; 62:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989; 11:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holter JC, Müller F, Bjørang O, et al. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway. BMC Infect Dis 2015; 15:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013; 8:e60273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao B, Zhao CJ, Yin YD, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis 2010; 51:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis 2007; 44:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janssens JP. Pneumonia in the elderly (geriatric) population. Curr Opin Pulm Med 2005; 11:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coon RG, Balansay MS, Faix DJ, et al. Chlamydophila pneumoniae infection among Basic Underwater Demolition/SEAL (BUD/S) candidates, Coronado, California, July 2008. Mil Med 2011; 176:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oktem IM, Ellidokuz H, Sevinc C, et al. PCR and serology were effective for identifying Chlamydophila pneumoniae in a lower respiratory infection outbreak among military recruits. Jpn J Infect Dis 2007; 60:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fajardo KA, Zorich SC, Voss JD, Thervil JW. Pneumonia Outbreak Caused by Chlamydophila pneumoniae among US Air Force Academy Cadets, Colorado, USA. Emerg Infect Dis 2015; 21:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassell K, Gacek P, Warren JL, et al. Association Between Sporadic Legionellosis and River Systems in Connecticut. J Infect Dis 2018; 217:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawai S, Ochi M, Nakagawa T, Goto H. Antimicrobial therapy in community-acquired pneumonia among emergency patients in a university hospital in Japan. J Infect Chemother 2004; 10:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paganin F, Lilienthal F, Bourdin A, et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J 2004; 24:779.
          </a>
         </li>
         <li class="breakAll">
          QualityNet. Specifications Manual. http://www.qualitynet.org/dcs/ContentServer?cid=1192804535739&amp;pagename=QnetPublic%2FPage%2FQnetTier3&amp;c=Page (Accessed on April 15, 2008).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ioannidis JP, Worthington M, Griffiths JK, Snydman DR. Spectrum and significance of bacteremia due to Moraxella catarrhalis. Clin Infect Dis 1995; 21:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verduin CM, Hol C, Fleer A, et al. Moraxella catarrhalis: from emerging to established pathogen. Clin Microbiol Rev 2002; 15:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aliberti S, Reyes LF, Faverio P, et al. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect Dis 2016; 16:1364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Self WH, Wunderink RG, Williams DJ, et al. Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes. Clin Infect Dis 2016; 63:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kallen AJ, Brunkard J, Moore Z, et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009; 53:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wunderink RG. How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy? Infect Dis Clin North Am 2013; 27:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lobo LJ, Reed KD, Wunderink RG. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest 2010; 138:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007; 45:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 Suppl 5:S378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stankovic C, Mahajan PV, Asmar BI. Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia. Curr Infect Dis Rep 2007; 9:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vayalumkal JV, Whittingham H, Vanderkooi O, et al. Necrotizing pneumonia and septic shock: suspecting CA-MRSA in patients presenting to Canadian emergency departments. CJEM 2007; 9:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007; 315:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li M, Cheung GY, Hu J, et al. Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains. J Infect Dis 2010; 202:1866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010; 375:1557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsen RJ, Kobayashi SD, Ayeras AA, et al. Lack of a major role of Staphylococcus aureus Panton-Valentine leukocidin in lower respiratory tract infection in nonhuman primates. Am J Pathol 2010; 176:1346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diep BA, Palazzolo-Ballance AM, Tattevin P, et al. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS One 2008; 3:e3198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peyrani P, Allen M, Wiemken TL, et al. Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Panton-Valentine leukocidin gene. Clin Infect Dis 2011; 53:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muller MP, Low DE, Green KA, et al. Clinical and epidemiologic features of group a streptococcal pneumonia in Ontario, Canada. Arch Intern Med 2003; 163:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Outbreak of group A streptococcal pneumonia among Marine Corps recruits--California, November 1-December 20, 2002. MMWR Morb Mortal Wkly Rep 2003; 52:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crum NF, Russell KL, Kaplan EL, et al. Pneumonia outbreak associated with group a Streptococcus species at a military training facility. Clin Infect Dis 2005; 40:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hooi LN, Looi I, Ng AJ. A study on community acquired pneumonia in adults requiring hospital admission in Penang. Med J Malaysia 2001; 56:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dooley KE, Golub J, Goes FS, et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34:1607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cesario TC. Viruses associated with pneumonia in adults. Clin Infect Dis 2012; 55:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oosterheert JJ, van Loon AM, Schuurman R, et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis 2005; 41:1438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 2011; 377:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karhu J, Ala-Kokko TI, Vuorinen T, et al. Lower respiratory tract virus findings in mechanically ventilated patients with severe community-acquired pneumonia. Clin Infect Dis 2014; 59:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008; 63:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jartti T, Jartti L, Peltola V, et al. Identification of respiratory viruses in asymptomatic subjects: asymptomatic respiratory viral infections. Pediatr Infect Dis J 2008; 27:1103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Templeton KE, Scheltinga SA, van den Eeden WC, et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005; 41:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falsey AR, Becker KL, Swinburne AJ, et al. Bacterial complications of respiratory tract viral illness: a comprehensive evaluation. J Infect Dis 2013; 208:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansson N, Kalin M, Hedlund J. Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis 2011; 43:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Self WH, Williams DJ, Zhu Y, et al. Respiratory Viral Detection in Children and Adults: Comparing Asymptomatic Controls and Patients With Community-Acquired Pneumonia. J Infect Dis 2016; 213:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein RA. Super-spreaders in infectious diseases. Int J Infect Dis 2011; 15:e510.
          </a>
         </li>
         <li class="breakAll">
          Turner RB. Rhinovirus. In: Principles and Practice of Infectious Diseases, 8th ed, Bennet JE, Dolin R, Blaser MJ (Eds), Elsevier, Philadelphia 2015. p.2113.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaiser L, Hayden FG. Editorial response: rhinovirus pneumonia--a clinical entity? Clin Infect Dis 1999; 29:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bastien N, Anderson K, Hart L, et al. Human coronavirus NL63 infection in Canada. J Infect Dis 2005; 191:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo PC, Lau SK, Tsoi HW, et al. Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia. J Infect Dis 2005; 192:1898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen KY, Ko SC, Hsueh PR, et al. Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. Chest 2001; 120:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valdivia L, Nix D, Wright M, et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis 2006; 12:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Roux A, Ewig S, García E, et al. Mixed community-acquired pneumonia in hospitalised patients. Eur Respir J 2006; 27:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutiérrez F, Masiá M, Rodríguez JC, et al. Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis 2005; 24:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karwa M, Currie B, Kvetan V. Bioterrorism: Preparing for the impossible or the improbable. Crit Care Med 2005; 33:S75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999; 281:1735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001; 285:2763.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Q fever: Information for Healthcare Providers. https://www.cdc.gov/qfever/healthcare-providers/index.html (Accessed on November 30, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. MMWR Recomm Rep 2013; 62:1.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6990 Version 61.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14683661" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25337751" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15875065" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Epidemiology of community-acquired pneumonia in Edmonton, Alberta: an emergency department-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29020164" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9737840" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The cost of treating community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26747825" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26172429" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20203464" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Burden of community-acquired pneumonia in North American adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18512336" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Deaths: final data for 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18512336" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Deaths: final data for 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23660396" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699079" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27418577" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24270053" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24957843" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23398862" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Is the present definition of health care-associated pneumonia the best way to define risk of infection with antibiotic-resistant pathogens?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22726368" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Does health care associated pneumonia really exist?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26527186" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The Microbiome and the Respiratory Tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15555822" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12821807" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Host innate defenses in the lung: the role of cytokines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15802161" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Pulmonary host defenses and factors predisposing to lung infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26903338" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10065680" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Risk factors for community-acquired pneumonia in adults: a population-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25294364" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Denture wearing during sleep doubles the risk of pneumonia in the very elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29095981" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30615036" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Association of Prescribed Opioids With Increased Risk of Community-Acquired Pneumonia Among Patients With and Without HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8052273" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1984946" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : An outbreak of pneumococcal pneumonia in two men's shelters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19787070" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Population-based surveillance for invasive pneumococcal disease in homeless adults in Toronto.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29644245" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Acute Onset of Pneumococcal Pneumonia Following Instrumentation of the Respiratory Tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25997673" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18266664" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Antipsychotic drug use and risk of pneumonia in elderly people.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20368647" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22786934" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22786936" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pneumonia and ACE inhibitors--and cough.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29028977" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20014950" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21337816" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Etiology of community-acquired pneumonia in hospitalized patients in northern Israel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21257985" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Microbial aetiology of community-acquired pneumonia and its relation to severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23855620" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29479548" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Incidence, Etiology, and Outcomes of Community-Acquired Pneumonia: A Population-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17989157" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22438343" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21460288" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Diagnostic tests for agents of community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18162378" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27448679" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17332485" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A worldwide perspective of atypical pathogens in community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15672850" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Etiology of community-acquired pneumonia treated in an ambulatory setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12196083" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29976651" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20363845" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Respiratory viruses in adults with community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26747826" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Editorial Commentary: The Modern Quest for the "Holy Grail" of Pneumonia Etiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26747826" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Editorial Commentary: The Modern Quest for the "Holy Grail" of Pneumonia Etiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The reliability of sputum typing and its relation to serum therapy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23523447" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21067350" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24092845" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged≥50 years with community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26747824" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Editorial Commentary: Quantitative Molecular Approach to Diagnosing Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2772465" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Community-acquired pneumonia requiring hospitalization: 5-year prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25887603" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23565216" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20540621" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17243062" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11462186" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15818184" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Pneumonia in the elderly (geriatric) population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21456360" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Chlamydophila pneumoniae infection among Basic Underwater Demolition/SEAL (BUD/S) candidates, Coronado, California, July 2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17515640" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : PCR and serology were effective for identifying Chlamydophila pneumoniae in a lower respiratory infection outbreak among military recruits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25988545" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Pneumonia Outbreak Caused by Chlamydophila pneumoniae among US Air Force Academy Cadets, Colorado, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29211873" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Association Between Sporadic Legionellosis and River Systems in Connecticut.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15614461" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Antimicrobial therapy in community-acquired pneumonia among emergency patients in a university hospital in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15516672" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15516672" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8562749" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Spectrum and significance of bacteremia due to Moraxella catarrhalis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11781271" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Moraxella catarrhalis: from emerging to established pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27593581" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27161775" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15614698" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16707043" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17431376" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18534715" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23398873" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20173050" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11888586" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17599308" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12228818" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18462093" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Pneumonia caused by methicillin-resistant Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17430704" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17626697" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Necrotizing pneumonia and septic shock: suspecting CA-MRSA in patients presenting to Canadian emergency departments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17234914" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21050125" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20206987" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Community-associated meticillin-resistant Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20093487" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Lack of a major role of Staphylococcus aureus Panton-Valentine leukocidin in lower respiratory tract infection in nonhuman primates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18787708" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21880581" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Panton-Valentine leukocidin gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12588207" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Clinical and epidemiologic features of group a streptococcal pneumonia in Ontario, Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12645840" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Outbreak of group A streptococcal pneumonia among Marine Corps recruits--California, November 1-December 20, 2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15712072" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Pneumonia outbreak associated with group a Streptococcus species at a military training facility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11732071" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : A study on community acquired pneumonia in adults requiring hospital admission in Penang.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12032896" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22423119" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Viruses associated with pneumonia in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16231254" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21435708" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Viral pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24729498" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Lower respiratory tract virus findings in mechanically ventilated patients with severe community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17573440" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Incidence and characteristics of viral community-acquired pneumonia in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18978518" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Identification of respiratory viruses in asymptomatic subjects: asymptomatic respiratory viral infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16007532" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23661797" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Bacterial complications of respiratory tract viral illness: a comprehensive evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21466255" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26180044" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Respiratory Viral Detection in Children and Adults: Comparing Asymptomatic Controls and Patients With Community-Acquired Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21737332" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Super-spreaders in infectious diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21737332" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Super-spreaders in infectious diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10530442" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Editorial response: rhinovirus pneumonia--a clinical entity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15655772" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Human coronavirus NL63 infection in Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16267760" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11451835" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16707052" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Coccidioidomycosis as a common cause of community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16585087" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Mixed community-acquired pneumonia in hospitalised patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15931452" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15640684" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Bioterrorism: Preparing for the impossible or the improbable.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10328075" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11386933" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Tularemia as a biological weapon: medical and public health management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11386933" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Tularemia as a biological weapon: medical and public health management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23535757" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
